Program
vepdegestrant
Also written as “ARV-471”, “Vepdegestrant” and “[phenyl-14C]ARV-471”.
Its studies are mostly in Breast Neoplasms, led by 3 companies.
Drug pageVepdegestrant: every studyAll 23 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizerits history only | 176 open or running | phase 3since Nov 16, 2022 | Jul 14, 2022 | Dec 4, 2026phase 1 · NCT07231991 |
| Arvinas Estrogen Receptorits history only | 20 open or running | phase 2since Aug 27, 2019 | Aug 27, 2019 | none ahead |
| Arvinas | 10 open or running | phase 2since Sep 7, 2022 | Sep 7, 2022 | none ahead |
Also a collaborator on its studies: Carrick Therapeutics.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Arvinas only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jul 21, 2022Named vepdegestrantINNProposed as its International Nonproprietary Name in WHO's List 127 · before, ARV-471
- Sep 7, 2022First study: phase 2 study in Breast NeoplasmsFirst studyNCT05549505 · 152 enrolled · United States, Georgia, Germany and more
TargetBeta
“An orally available hetero-bifunctional molecule and selective estrogen receptor (ER) alpha-targeted protein degrader, using the proteolysis targeting chimera (PROTAC) technology, ”NCIt, by rule
Other programs on ESR1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Ethinyl Estradiolrule | Johnson & Johnson | phase 4 | 70 |
| Estradiolrule | Novo Nordisk | phase 4 | 69 |
| Fulvestrantrule | AstraZeneca | phase 4 | 30 |
| Tamoxifenrule | AstraZeneca | phase 4 | 21 |
| Clomiphenerule | Hamad Medical | phase 4 | 3 |
| camizestrantrule | AstraZeneca | phase 3 | 18 |
| giredestrant | Hoffmann-La Roche | phase 3 | 17 |
| HRS-8080 | Jiangsu HengRui Medicine | phase 3 | 13 |
| elacestrantrule | Menarini Group | phase 3 | 12 |
| Imlunestrantrule | Eli Lilly | phase 3 | 12 |
| taragarestrantrule | InventisBio | phase 3 | 5 |
| SIM0270rule | Simcere Pharmaceutical Group | phase 3 | 5 |
Studies
The one study Arvinas leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05549505Breast Neoplasms · United States, Georgia, Germany and more | 2 | Completed | Jul 13, 2024 | 152 |
How it is read
Names in the registry
- “ARV-471”, 7 entries
- “vepdegestrant”, 6 entries
- “Vepdegestrant”, 4 entries
- “[phenyl-14C]ARV-471”, 1 entry
- “[oxoisoindolin-14C]ARV-471”, 1 entry
Conditions, from the studies’ own filings
- Breast Neoplasms, 11 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.